NCT04958967View on ClinicalTrials.gov

Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 1, 2021

Primary Completion Date

May 1, 2022

Study Completion Date

August 1, 2022

Conditions
NSCLC
Interventions
DRUG

Furmonertinib 240mg

treated subjects will receive Furmonertinib 240mg/day

DRUG

Furmonertinib 160mg

treated subjects will receive Furmonertinib 160mg/day

Trial Locations (1)

Unknown

Shanghai Chest hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Allist Pharmaceuticals, Inc.

INDUSTRY

NCT04958967 - Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation | Biotech Hunter | Biotech Hunter